RTW Investments LP Acquires 95,001 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

RTW Investments LP boosted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 5.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,945,649 shares of the company's stock after acquiring an additional 95,001 shares during the quarter. RTW Investments LP owned 5.56% of Oruka Therapeutics worth $37,726,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ORKA. China Universal Asset Management Co. Ltd. bought a new position in Oruka Therapeutics during the 4th quarter valued at about $144,000. AlphaCentric Advisors LLC acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth approximately $119,000. Charles Schwab Investment Management Inc. bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at approximately $303,000. Vanguard Group Inc. boosted its holdings in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after acquiring an additional 1,572,853 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Oruka Therapeutics in the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Trading Up 2.5%

Oruka Therapeutics stock traded up $0.25 during mid-day trading on Monday, hitting $10.31. The stock had a trading volume of 160,168 shares, compared to its average volume of 227,762. The stock has a 50-day simple moving average of $9.86 and a two-hundred day simple moving average of $14.68. The stock has a market capitalization of $386.02 million, a PE ratio of -1.65 and a beta of 0.25. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. Sell-side analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ORKA has been the subject of several research analyst reports. Wolfe Research began coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.